It’s being hailed as the first new Alzheimer’s treatment in 18 years and the first to slow disease progression. But some experts say there’s not enough evidence that Aducanumab actually works. Dr. Sharon Cohen, director of the Toronto Memory Program, was a clinical trial investigator in the drug’s phase 3 trial and has a number of patients who are taking it. Libby Znaimer reached her in Toronto.

AND

New research suggests there is a hard upper limit to the human life span - but according to the study in Nature Communications, it could be as high as 150 years! Dr. Jay Olshansky is a Professor at the University of Illinois at Chicago. His work focuses on estimating the upper limits of longevity and what that means for the aging population.